Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 142

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 142
---
 and would likely
be placed in administration.

Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement
and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical
trials. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner
than we currently expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities,
our business, financial condition and results of operations could be materially adversely affected.

If
we raise additional funds through the issuance of debt securities or additional equity securities, it could result in dilution to our
existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our Ordinary Shares
(including the Depositary Shares) and could contain covenants that would restrict our operations and potentially impair our competitiveness,
such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly
harm our business, financial condition and prospects.

| 72 |

In our opinion, the environment
for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities
with other companies with limited or no access to financing, as noted above, any attendant financings by us are likely to be dilutive.
We continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Company.
Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any alternative
courses of action to finance the Company would be successful. This requirement for additional financing in the short term represents a
material uncertainty that may cast significant doubt upon our ability to continue as a going concern. Should it become evident in the
future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then
the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under
paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be stated at net realizable
value and all liabilities would be accelerated to current liabilities. As a result of the foregoing, our independent registered public